In Vitro Activity of Dalbavancin against Drug-Resistant Staphylococcus aureus Isolates from a Global Surveillance Program

August 17, 2015 at 10:10 pm

Antimicrobial Agents and Chemotherapy AUG. 2015 V.59 N.8 P.5007-5009

Sandra P. McCurdy, Ronald N. Jones, Rodrigo E. Mendes, Sailaja Puttagunta, and Michael W. Dunne

aDurata Therapeutics, Branford, Connecticut, USA

bJMI Laboratories, North Liberty, Iowa, USA

In over a decade (2002 to 2012) of Staphylococcus aureus surveillance testing on 62,195 isolates, dalbavancin was demonstrated to be active against isolates that were either susceptible or nonsusceptible to daptomycin, linezolid, or tigecycline.

Nearly all (99.8%) multidrug-resistant methicillin-resistant S. aureus isolates were inhibited by dalbavancin at ≤0.12 μg/ml (MIC50/90, 0.06/0.06 μg/ml), the current U.S. Food and Drug Administration (U.S. FDA) breakpoint.

Overall, only 0.35% of the monitored S. aureus isolates had a dalbavancin MIC of either 0.25 or 0.5 μg/ml (i.e., were nonsusceptible).

PDF

http://aac.asm.org/content/59/8/5007.full.pdf

Entry filed under: Antimicrobianos, Bacterias, Bacteriemias, Metodos diagnosticos, Resistencia bacteriana. Tags: .

Editor’s Choice: Nitrofurantoin revisited: a systematic review and meta-analysis of controlled trials Community-Acquired Pyelonephritis in Pregnancy Caused by KPC-Producing Klebsiella pneumoniae


Calendar

August 2015
M T W T F S S
« Jul   Sep »
 12
3456789
10111213141516
17181920212223
24252627282930
31  

Most Recent Posts


%d bloggers like this: